Key Takeaways for Neratinib Plus T-DM1 Combination in Breast Cancer
Jame Abraham, MD, discusses the key takeaways from the phase Ib study of trastuzumab emtansine in combination with neratinib in patients with HER2-positive breast cancer.
Jame Abraham, MD, professor of medicine at the Cleveland Clinic and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses the key takeaways from the phase Ib study of trastuzumab emtansine (T-DM1) in combination with neratinib (Nerlynx) in patients with HER2-positive breast cancer.
First, Abraham says that the trial shows T-DM1 is an active regimen in combination with neratinib for patients who progress or are refractory to trastuzumab (Herceptin) and pertuzumab (Perjeta). With a dose of neratinib at 160 mg, the combination had deep responses in this patient population.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
